Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1904 in Second-line CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma
NCT06649292Phase 3Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2024
- Primary completion
- Sep 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of garetatug rezetecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Hengrui Therapeutics. Started Nov 2024; status: recruiting.
02
Drugs
garetatug rezetecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06649292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06649292.